Please note!
This fact brief was originally published as an experiment to test the concepts behind fact briefs.
Readers should be aware that while there is still a lot of useful information in fact briefs like this one, not all of them reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date, don't hesitate to contact us at support@gigafact.org.
Is camostat being studied as a potential drug to combat coronavirus?
Thursday, April 16, 2020
By Jay Majithia
Copy link
Copy featured image
YES
Camostat, made by a Japanese pharamaceutical company, is what's known to scientists as a serine protease inhibitor. It is not approved by the FDA for use in the U.S.
Camostat has previously been noted for its effects against the virus that caused the 2003 SARS epidemic. Research into the drug's potential against the coronavirus has been spurred by a March 2020 report of the drug's effectiveness in a laboratory test against the virus causing the 2020 pandemic. It remains to be proved whether camostat can help fight coronavirus in humans. What appears to be the first thorough clinical trial is scheduled to be finished by May 2021.
This fact brief is responsive to conversations such as this one.
Sources
ABOUT THE CONTRIBUTOR
Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Foundry. Over the course of these two years, Gigafact Foundry writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Foundry reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.
FACT BRIEF BY
